Berlex' Angeliq Is "Approvable"; More Manufacturing Data Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
The company anticipates a 2005 approval for the hormone replacement therapy for the lowest dose submitted. The firm is also touting a potential antihypertensive effect with Angeliq for higher doses.